Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics (NCT05490888)
A Phase 1 Open Label Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PHIN-214 in Adults With Child Pugh A and B Cirrhosis
🩺 Plain-English Summary (8th-Grade Level)
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.
Who can join: Review the eligibility criteria below.
Location: Arizona Liver Health — Chandler, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Arizona Liver Health — Chandler, Arizona
- Southern California Research Center — Coronado, California
- Tandem Clinical Research — Marrero, Louisiana
- Mayo Clinic — Rochester, Minnesota
- Cleveland Clinic — Cleveland, Ohio
- University of Pennsylvania — Philadelphia, Pennsylvania
- Methodist Health System, Dallas Medical Center — Dallas, Texas
- VA North Texas Healthcare System — Dallas, Texas
- Texas Liver Institute — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (206) 568-1450
Email: PHIN.214001@pharmain.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cirrhosis, Liver
- LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study — Ann Arbor, Michigan
- ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement — Phoenix, Arizona
- Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease — Ann Arbor, Michigan
- Angiotensin 2 for AKI After OLT — Los Angeles, California
- Erlotinib for Hepatocellular Carcinoma Chemoprevention — Dallas, Texas
Explore by condition: All Cirrhosis, Liver clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.